Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733143 | 1.00 | DYRK1A (0.60) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| SCHEMBL30337203 | 0.90 | DYRK1A (0.70) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| SCHEMBL30935767 | 0.90 | DYRK1A (0.63) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| SCHEMBL4402187 | 0.90 | DYRK1A (0.63) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| Hydrochloric Acid SCHEMBL10461111 | 0.87 | DYRK1A (0.61) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| SCHEMBL29432628 | 0.84 | DYRK1A (0.58) | DYRK1AMKNK1MKNK2PDPK1NOS3 | |
| SCHEMBL15649966 | 0.84 | DYRK1A (0.63) | DYRK1AMKNK1MKNK2AAK1MAPT | |
| SCHEMBL1836488 | 0.84 | DYRK1A (0.58) | DYRK1AMKNK1MKNK2PDPK1NOS3 | |
| Bromide SCHEMBL5752578 | 0.82 | DYRK1A (0.56) | DYRK1AMKNK1MKNK2PDPK1NOS3 | |
| SCHEMBL18854871 | 0.80 | MKNK1 (0.62) | DYRK1AMKNK1MKNK2AAK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114904356-B | Method for separating nitrogen and oxygen | 中国科学院大连化学物理研究所 | 2024-03-26 | — | — | CN | disclosed |
| EP-3185330-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3246963-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-113956236-B | Phthalimide compound and application thereof | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| CN-113929662-B | Succinimide or maleimide compound and use thereof | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| CN-114904356-A | Method for separating nitrogen and oxygen | 中国科学院大连化学物理研究所 | 2022-08-16 | — | — | CN | disclosed |
| CN-109867661-B | Amide compounds for regulating WNT signal pathway and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| CN-114420633-A | Copper deposition in wafer level packaging of integrated circuits | 麦克德米德乐思公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113956236-A | Phthalimide compound and application thereof | 中国医学科学院药物研究所 | 2022-01-21 | — | — | CN | disclosed |
| US-7125888-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| EP-1503757-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050176753-A1 | controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| EP-1503757-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| WO-2003092595-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176753-A1 | controlling signal transduction; anticancer agents; antitumor agnets; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents | IRAK4, MAP3K4, MAP3K1 | DYRK1A 1305/4885MKNK1 155/4885MKNK2 275/4885 |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | DYRK1A 916/4885MKNK1 4549/4885MKNK2 4624/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | DYRK1A 1974/4885MKNK1 3596/4885MKNK2 3452/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DYRK1A 1587/4885MKNK1 2081/4885MKNK2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.